Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 19/20 | 0.64 |
| ▸ | EDNRB | P24530 | 6/20 | 0.62 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | DHPS | P49366 | 1/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.61 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795081 | 0.91 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL14201214 | 0.90 | EDNRA (0.76) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1258816 | 0.87 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Tezosentan SCHEMBL6963555 | 0.85 | EDNRA (0.79) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4524 | 0.85 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29409604 | 0.85 | EDNRA (0.80) | EDNRAEDNRB | |
| SCHEMBL6969968 | 0.84 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL6959738 | 0.84 | EDNRA (0.67) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL6962526 | 0.84 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Tezosentan SCHEMBL387772 | 0.84 | EDNRA (0.79) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885EDNRB 502/4885ABCC3 1458/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885ABCC3 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.